Clinical Trial Update: Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging [Phase 3]

View source ↗

Summary

Phase 3 study evaluating gadobutrol 1.0 mmol/mL (Gadavist) for central nervous system imaging reported safety and efficacy results. Results were posted on 2012-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Diseases

Drugs mentioned

• Gadavist (gadobutrol)

Snippet

Sponsor: Bayer | Conditions: Diagnostic Imaging, Central Nervous System Diseases | Phase 3 | Status: COMPLETED | Results posted: 2012-03-06